RxDoctor Payments DataLook up a doctor →

Ashwani Kumar, MD

Interventional Cardiology · Richmond, VANPI 1134313216

Payments from drug & device makers

$34,776in general payments, 2019–2025

Across 390 payments — averaging $89.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$25K
  • Abbott$4K
  • Terumo Medical Corporation$1K
  • Novartis$734
  • Pfizer$358
  • Cardiovascular Systems Inc.$317
  • plus $4K from 41 others

What the payments were for

  • Consulting fees$3,37510%
  • Travel & lodging$21,49962%
  • Food & beverage$9,86228%
  • Education$400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,776 in reported general payments places this provider in the 75th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$880,339
Medicare patients
1,618
Services billed
9,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban333$280,778
EntrestoSacubitril/Valsartan124$97,784
XareltoRivaroxaban92$89,476
Repatha SureclickEvolocumab83$58,291
BrilintaTicagrelor40$18,880
FarxigaDapagliflozin Propanediol16$9,468
Repatha SyringeEvolocumab15$9,260
Ranolazine ErRanolazine43$3,897
Bumetanide110$3,577
ClopidogrelClopidogrel Bisulfate281$2,871
Metoprolol Succinate251$2,549
Amiodarone Hcl55$2,010
Diltiazem 24hr Er (Cd)Diltiazem Hcl47$1,791
Rosuvastatin Calcium139$1,462
Atorvastatin Calcium233$1,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$358$280,778333 claims
NovartisEntresto$734$97,784124 claims
Johnson & JohnsonXarelto$227$89,47692 claims
AstraZenecaBrilinta, Farxiga$190$28,34856 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →